IQM-QUANTUM-COMPUTERS
12.11.2021 11:02:06 CET | Business Wire | Press release
As part of its long-term growth strategy, IQM Quantum Computers announces the operation of its new state-of-the-art fabrication and cryogenic characterization facility, which will expand its quantum processor production capacity. This new facility is situated close to its headquarters and quantum labs in Espoo, Finland and marks the company’s largest investment to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211112005477/en/
Today, IQM has started its pilot line and will expand with further fabrication lines in the future. These facilities will substantially accelerate the company’s quantum processor design cycle and increase its microelectronics fabrication capacity to keep pace with the dramatic technology shifts underway within national quantum programs, high-performance computing centers, and increasing demand from the industrial customers. In addition, the facilities will ensure the highest industry-level quality required for quantum computing.
“We continue to see increasing demand for our on-premises quantum computers across Europe and globally. Today, we are announcing our largest-ever investment in production to dramatically increase our quantum processor supply and build quantum computers of the future,” said Dr. Jan Goetz, CEO and co-founder of IQM Quantum Computers.
“This investment in equipment, infrastructure and our workforce increases our fabrication, new material research, 3D integration and product delivery capabilities. Today, we’ve started the first phase of our fabrication facility and we plan to continuously learn, and invest in further expansion.”
The pilot line at this facility will be ramped-up over the coming months, and it is expected to reach maximum production capacity during 2022.
This new facility will create high-tech job opportunities and serve as an advanced manufacturing workforce-development initiative. IQM plans to partner with the Finnish and European ecosystems and prepare its workforce for the long-term, high-quality employment and growth opportunities the new facilities will present.
This is another strategic step to strengthen IQM’s position as the category leader for on-premises quantum computers in Europe and provides a strong competitive advantage over other quantum startups.
Facts:
- Location: Espoo, Finland
- Investment: € 20 Million
- Area: 560 m2
About IQM Quantum Computers:
IQM is the Pan-European category leader in building quantum computers.
IQM delivers on-premises quantum computers for supercomputing centers and research laboratories and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique, application-specific, co-design approach.
IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium was awarded a project to commercialize application-specific quantum processors by the German Ministry of Education and Research in February 2021.
IQM has raised €71 million from private and public funding and has offices in Espoo, Finland; Munich, Germany; and Bilbao, Spain.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
www.meetiqm.com
You can watch the complete recording of the launch event here: https://youtu.be/EUvAfl7a0Vs
View source version on businesswire.com: https://www.businesswire.com/news/home/20211112005477/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom